首页> 外文期刊>Leukemia and lymphoma >Post-transplant immune reconstitution after unrelated allogeneic stem cell transplant in patients with acute myeloid leukemia.
【24h】

Post-transplant immune reconstitution after unrelated allogeneic stem cell transplant in patients with acute myeloid leukemia.

机译:无关的同种异体干细胞移植后急性髓样白血病患者的移植后免疫重建。

获取原文
获取原文并翻译 | 示例
           

摘要

We evaluated immune recovery in 67 patients with acute myeloid leukemia (AML) with a median age of 40 years (4-69) following allo-SCT after reduced (n = 35) or myeloablative (n = 32) conditioning. The following lymphocyte populations were determined on days +30, +90, +180, +270, and +365 by flow associated cell sorting: CD3+, CD3+CD4+, CD3+CD8+, CD3+CD4+/CD3+CD8+ ratio, CD3-CD56+, and CD19+ cells. Peripheral blast count >5% was related to lower number of CD3+CD4+ (day +30) and NK cells (day +180; p = 0.02). Intensity of conditioning did not have any significant impact on the kinetics of immune recovery. Patients with normal CD3+CD4+/CD3+CD8+ ratio (day +30) and NK cell count (day +90; p <0.05) experienced better survival than those with decreased parameters. Post-transplant sepsis/severe infections impaired CD3+CD8+ (day +90; p = 0.015) and CD19+ (day +90; p = 0.02) recovery. Relapse in patients following allo-SCT showed an association with decreased numbers of CD19+ (day +270) and NK cells (day +365). Acute GvHD (II-IV) was accompanied by reduced CD19+ and CD3+CD4+ cells. Thus, the evaluation of post-transplant immune reconstitution in patients with AML might improve risk stratification concerning either relapse or TRM and remains to be further explored.
机译:我们评估了67例急性骨髓性白血病(AML)患者在进行异体SCT缓解(n = 35)或清髓性(n = 32)治疗后的中位年龄为40岁(4-69)的免疫恢复。在第30天,+ 90,+ 180,+ 270和+365天通过流相关细胞分选确定了以下淋巴细胞群:CD3 +,CD3 + CD4 +,CD3 + CD8 +,CD3 + CD4 + / CD3 + CD8 +比,CD3- CD56 +和CD19 +细胞。周围胚细胞计数> 5%与CD3 + CD4 +(第+30天)和NK细胞(第+180天; p = 0.02)的数量减少有关。调节强度对免疫恢复的动力学没有显着影响。 CD3 + CD4 + / CD3 + CD8 +比率正常的患者(第30天)和NK细胞计数(第90天; p <0.05)的患者比参数降低的患者生存期更好。移植后败血症/严重感染会损害CD3 + CD8 +(第90天; p = 0.015)和CD19 +(第90天; p = 0.02)。异基因SCT后患者的复发显示与CD19 +(第+270天)和NK细胞(第+365天)数量减少有关。急性GvHD(II-IV)伴有CD19 +和CD3 + CD4 +细胞减少。因此,对AML患者移植后免疫重建的评估可能会改善有关复发或TRM的风险分层,有待进一步探索。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号